TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01416493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: s.c. injections of bovine intestinal Alkaline Phosphatase
Description: daily subcutaneous treatment with two injections of 2000IU bIAP for three days
Study: NCT04429568

Intervention type: OTHER
Group type: OTHER
Intervention: Smoked Cannabis
Description: Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff.

Intervention type: OTHER
Group type: OTHER
Intervention: Smoked Cannabis
Description: Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff.

Intervention type: OTHER
Group type: OTHER
Intervention: Smoked Cannabis
Description: Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff.

Intervention type: OTHER
Group type: OTHER
Intervention: Vaped Cannabis
Description: Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff. All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.

Intervention type: OTHER
Group type: OTHER
Intervention: Vaped Cannabis
Description: Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff. All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.
Study: NCT01423435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-100STP
Description: oral
Study: NCT00228904

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients diagnosed with diabetic neuropathy are tested at baseline and every six months thereafter to compare to patients treated with pulsatile intravenous insulin therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsatile IV insulin delivery (humalog, humulin, novolog)
Description: Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after start of treatment of pulsatile intravenous insulin therapy
Study: NCT04429568

Intervention type: OTHER
Group type: OTHER
Intervention: Vaped Cannabis
Description: Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff. All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.

Intervention type: OTHER
Group type: OTHER
Intervention: Tobacco Cigarette
Description: Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.
Study: NCT02555540

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Randomised assignment
Study: NCT03918551

Intervention type: DRUG
Group type: OTHER
Intervention: Febuxostat
Description: Febuxostat is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 120 mg of febuxostat.

Intervention type: DRUG
Group type: OTHER
Intervention: Febuxostat
Description: Febuxostat is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 120 mg of febuxostat.

Intervention type: DRUG
Group type: OTHER
Intervention: Adenuric
Description: Adenuric is manufactured by Menarini - Von Heyden GmbH, Germany (MAH: Menarini International Operations Luxembourg S.A., Luxembourg). Each film-coated tablet contains 120 mg of febuxostat.
Study: NCT04429568

Intervention type: OTHER
Group type: OTHER
Intervention: Tobacco Cigarette
Description: Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Tobacco Cigarette
Description: Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.
Study: NCT04947228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trackPAD
Description: TrackPAD is a smartphone app to provide PAD-specific support for SET
Study: NCT02008890

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab 300mg
Description: Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered
Study: NCT03918551

Intervention type: DRUG
Group type: OTHER
Intervention: Adenuric
Description: Adenuric is manufactured by Menarini - Von Heyden GmbH, Germany (MAH: Menarini International Operations Luxembourg S.A., Luxembourg). Each film-coated tablet contains 120 mg of febuxostat.
Study: NCT01749176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS texting intervention
Study: NCT04664023

Intervention type: PROCEDURE
Intervention: Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.
Description: 40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis

Intervention type: PROCEDURE
Intervention: Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.
Description: 40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
Study: NCT02008890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 300mg
Description: Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab 150mg
Description: secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 150mg
Description: secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: secukinumab placebo s.c. (two PFS injections of placebo) self-administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: secukinumab placebo s.c. (two PFS injections of placebo) self-administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: secukinumab placebo s.c. (two PFS injections of placebo) self-administered
Study: NCT01610427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
Study: NCT00499031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study: NCT01368367

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive exercise
Description: Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intensive exercise
Description: Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
Study: NCT02250105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARI-3037MO
Description: Lipid lowering

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive
Study: NCT04664023

Intervention type: PROCEDURE
Intervention: Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.
Description: 40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
Study: NCT05890443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Before starting the research, self-management training in rehabilitation was given to both groups. While the exercise practices were carried out in the experimental group, encouraging reminders were made by following the background web page created in the experimental group.
Study: NCT00970879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cotrimoxazole
Description: 800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cotrimoxazole
Description: 800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cotrimoxazole
Description: 800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mefloquine
Description: mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mefloquine
Description: mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy
Study: NCT01389830

Intervention type: BEHAVIORAL
Intervention: Telephone Survey
Description: Telephone interviews (survey) at baseline taking approximately 30-40 minutes to complete; follow-up monthly surveys for cancer patients take 20-30 minutes to complete, follow ups until 12 months or death.

Intervention type: BEHAVIORAL
Intervention: Telephone Survey
Description: Telephone interviews (survey) at baseline taking approximately 30-40 minutes to complete; follow-up monthly surveys for cancer patients take 20-30 minutes to complete, follow ups until 12 months or death.
Study: NCT03035292

Intervention type: DIAGNOSTIC_TEST
Intervention: Red-reflex assessment
Description: The red reflex was examined in the standard manner using direct ophthalmoscope by medical student examiner

Intervention type: DIAGNOSTIC_TEST
Intervention: Infrared-reflex assessment
Description: The infrared reflex was examined using a modified smart phone camera by a medical student examiner
Study: NCT02611739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medi-Port
Description: Treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medi-Port
Description: Control
Study: NCT01241357

Intervention type: DEVICE
Intervention: Hepatic biomagnetic susceptibility measurement
Description: Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
Study: NCT02974790

Intervention type: PROCEDURE
Intervention: Echocardiography
Description: Two-dimensional imaging echocardiography
Study: NCT02377154

Intervention type: DEVICE
Group type: OTHER
Intervention: Slit lamp
Description: Examination of cornea

Intervention type: DEVICE
Group type: OTHER
Intervention: Autorefractor
Description: Measurement of refraction

Intervention type: DEVICE
Group type: OTHER
Intervention: IOLMaster 500
Description: Measurement of axial length and white-to-white distance; Keratometry; IOL calculation

Intervention type: DEVICE
Group type: OTHER
Intervention: Pentacam HR
Description: Measurement of white-to-white distance; Keratometry

Intervention type: DEVICE
Group type: OTHER
Intervention: LenStar LS900
Description: Measurement of axial length and white-to-white distance; Keratometry; IOL calculation

Intervention type: DEVICE
Group type: OTHER
Intervention: VERION Image Guided System
Description: Measurement of white-to-white distance; Keratometry; IOL calculation with axial length value of IOLMaster 500
Study: NCT03638895

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECAL Indirect Calorimeter
Description: The ECAL is an open-circuit portable indirect calorimeter that measures both volume of CO2 expired and O2 consumed using a small mixing chamber. Participants will breathe through a mouthpiece with a nose clip applied whilst lying in a restful and comfortable position for 15 minutes. ECAL device will provide breath-by-breath measurements of the resting energy expenditure and respiratory quotient which will allow both practitioners and participants to monitor their metabolic health and compare the effect of dietary and physical activity intervention over the course of the structured intensive lifestyle intervention (24-weeks).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet, exercise & behaviour modification therapy
Description: Standard care (SC) - participants receive standard care (diet, exercise \& behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
Study: NCT05759416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin2%gel
Description: Intra-pocket application of 2% Melatonin gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: placebo intra-pocket application
Study: NCT00868855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradykinin
Description: Bradykinin, 0.2 ug - 2ug/minute, one time intracoronary infusion over 6 minutes. Drug (bradykinin) will be infused into the left main coronary artery via diagnostic catheter (JL4) at an escalating rate of 0.2, 0.6, 2 g/ml (1ml/min). A 5F Multipurpose catheter will be advanced to coronary sinus for blood sampling.
Study: NCT03191487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ChimioPal
Description: Systematic collection of clinical and laboratory toxicities (TXs) during the 2-4 days preceding a chemotherapy (CT) session (48H before a session (D-2 towards the end of the afternoon) and a maximum of 96h before sessions occurring on Mondays (D-4 towards the end of the afternoon). Clinical TX data will be collected via ChimioPal (a self-questionnaire administered by smartphone) and laboratory TX data will be collected via Apicrpyt (secure messaging service) or a fax-to-email service. Data flow management by a nurse dedicated to this activity in each centre will be implemented. If the results of the assessment do not authorize CT, additional assessments may be prescribed. If the experimental data transmission does not occur, the usual pathways will be implemented.~Patient training on how to use a smart phone and the questionnaire will be performed by a nurse before the start of the first chemotherapy session, with reminders at the following sessions if required.
Study: NCT01749176

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control-Usual Care
Study: NCT01907737

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).

Intervention type: OTHER
Group type: OTHER
Intervention: Active tDCS
Description: Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active PNS
Description: Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.

Intervention type: OTHER
Group type: OTHER
Intervention: Active PNS
Description: Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.

Intervention type: OTHER
Group type: OTHER
Intervention: Sham tDCS
Description: In sham tDCS, no current will be delivered through the tDCS device.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: In sham tDCS, no current will be delivered through the tDCS device.

Intervention type: OTHER
Group type: OTHER
Intervention: Sham PNS
Description: No current will be delivered to the radial, ulnar and median nerves.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham PNS
Description: No current will be delivered to the radial, ulnar and median nerves.
Study: NCT00935987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT387
Description: For the Part 1 dose-escalation portion of the study, patients will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 100 mg/day. CYT387 will be orally self-administered as a single daily dose beginning on Day 1 of the study, and thereafter at approximately the same time each day of the 28-day cycle. It is recommended that all doses be preceded by a 2-hour fast from food and beverages, and be followed by a 1-hour post-dose fast from food and beverages.~Twenty additional patients will be assigned to a 150 mg BID (twice daily) dosing schedule. CYT387 will be orally self-administered twice-daily with doses approximately 10-12 hours apart beginning on Day 1 of the study, and thereafter at approximately the same times each day of the 28-day cycle.~For the Part 2 dose confirmation portion of the study, patients will be assigned to either 150 mg or 300 mg QD (once daily) dose groups.
Study: NCT04664023

Intervention type: PROCEDURE
Intervention: Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers
Description: 40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
Study: NCT02493725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04164888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIVI 007
Description: hypercholesterolemia agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIVI 007
Description: hypercholesterolemia agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIVI 007
Description: hypercholesterolemia agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CIVI 007
Description: hypercholesterolemia agent
Study: NCT04381585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A MINI DISTRACTOR WITH A SUBMERGED ACTIVATION COMPONENT
Description: Mini distractor is used to regenerate alveolar bone which is resorbed due various reasons. The distractor uses a winch-like submucosal activation component which is buried in the tissue; Flicking the winch turns the screw which moves the segment upwards in the direction of black arrow increasing height.
Study: NCT01842984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-SOCIAL intervention
Description: The I-SOCIAL intervention is based on findings from Cohen-Mansfield and Parpura-Gill (2007), which highlighted the important role of barriers in contributing to loneliness in older persons. These barriers include a perceived lack of opportunities for social contacts, low social self-efficacy, and health and mobility difficulties. The intervention includes: (1) identifying the barriers for the specific person; (2) up to 10 meetings with an activities counselor. The meetings include discussions concerning options for social contacts and use of techniques and resources to tackle the barriers; and (3) group meetings of participants and the activities counselors in order to provide a concrete social event and as a venue to discuss barriers and ways to address them.
Study: NCT04163692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises
Description: Following intructions have been performed by patients:~* Punch your hands and contract your forearm~* Punch your hands, push your elbow towards the seat~* Bend your elbows~* Push your shoulders back~* Press your knee down and pull your toes towards you~* Pull your knees towards you and push your feet down~* Tighten your hips~* Push your head back~* Lift your eyebrows~* Make wrinkles on your nose~* Tighten your teeth~* Push your chin down~* Close your eyes and think of good things.